BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 38551786)

  • 1. Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.
    Harrington J; Felker GM; Januzzi JL; Lam CSP; Lingvay I; Pagidipati NJ; Sattar N; Van Spall HGC; Verma S; McGuire DK
    Curr Cardiol Rep; 2024 Mar; 26(3):61-71. PubMed ID: 38551786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
    Urva S; Levine JA; Schneck K; Tang CC
    Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A new era for glucagon-like peptide-1 receptor agonists].
    Neuville MF; Paquot N; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on peptide-based therapies for type 2 diabetes and obesity.
    Bailey CJ; Flatt PR; Conlon JM
    Peptides; 2023 Mar; 161():170939. PubMed ID: 36608818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
    Nauck MA; D'Alessio DA
    Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
    Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
    Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
    Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
    Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity pharmacotherapy: incretin action in the central nervous system.
    Boer GA; Hay DL; Tups A
    Trends Pharmacol Sci; 2023 Jan; 44(1):50-63. PubMed ID: 36462999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin Analogs for Weight Management in Adults Without Diabetes.
    Lobkovich A; Kale-Pradhan P; Lipari M
    Ann Pharmacother; 2024 Apr; 58(4):398-406. PubMed ID: 37522468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
    Mora PF; Johnson EL
    Endocr Pract; 2017 Jan; 23(1):89-99. PubMed ID: 27819769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tirzepatide: A Review in Type 2 Diabetes.
    France NL; Syed YY
    Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
    Gallwitz B
    Front Endocrinol (Lausanne); 2022; 13():1004044. PubMed ID: 36313764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.
    Scheen AJ
    Ann Endocrinol (Paris); 2023 Apr; 84(2):316-321. PubMed ID: 36639119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
    Doggrell SA
    Expert Opin Investig Drugs; 2023 May; 32(5):355-359. PubMed ID: 37086147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.
    Quddos F; Hubshman Z; Tegge A; Sane D; Marti E; Kablinger AS; Gatchalian KM; Kelly AL; DiFeliceantonio AG; Bickel WK
    Sci Rep; 2023 Nov; 13(1):20998. PubMed ID: 38017205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
    Herrou J; Mabilleau G; Lecerf JM; Thomas T; Biver E; Paccou J
    Calcif Tissue Int; 2024 Feb; 114(2):86-97. PubMed ID: 37999750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.